Overview
I am a graduate of Columbia University (BS, 1971) and Weill Cornell Medical College (MD, 1975). Upon completion of postdoctoral training, I joined the Weill Cornell faculty and returned to my native Haiti to establish the Weill Cornell Infectious Diseases Unit. In 1982, I recognized and provided the first comprehensive description of AIDS in the developing world and founded the organization GHESKIO. Three decades later, GHESKIO provides free testing and treatment for HIV infection for over 40,000 persons annually and treats over 3,000 patients with TB. GHESKIO also provides comprehensive services to its adjacent slum population, including providing health care, tuberculosis case finding, reproductive health and family planning, sexual health education, micro credit financing, and nutritional support. GHESKIO is also implementing programs to increase HIV testing of adolescents and to improve care for those infected. GHESKIO was recognized with the 2010 Gates Award for Global Health for outstanding global health service, research, and training. My research interests are the design of therapeutic and preventive health interventions for people in resource poor countries.
Highlights
- 1Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
- 2
- 3The New England journal of medicine · 2023
Publications
319 publications
Funding
33 grantsView NIH portfolio on RePORTER ↗
Active
12 grants- Co-IP01AI202868-06Determinants of TB Control, Relapse, and ReinfectionNational Institute of Allergy and Infectious Diseases · 2026–2031
- KPR01AI176943-03S1Impact of TB coinfection on HIV reservoir - Foreign SupplementNational Institute of Allergy and Infectious Diseases · 2023–2028· 2 renewals
- KPR01HL143788-08S1A longitudinal cohort study to evaluate cardiovascular risk factors and disease in Haiti - 2 - Foreign supplementNational Heart, Lung, and Blood Institute · 2018–2028· 3 renewals
- Sub-PIU01Al069923-22Caribbean, Central, and South America network for HIV Epidemiology (CCASAnet)National Institute of Allergy and Infectious Diseases · 2026–2028 · via Vanderbilt University Medical Center
- MPID43TW011972-05S2Cardiovascular Disease Research Training Program in Haiti - Foreign Subsite SupplementFogarty International Center · 2021–2027· 3 renewals
- MPIP30AI168433-01Tri-Institutional Tuberculosis Research Advancement CenterNational Institute of Allergy and Infectious Diseases · 2022–2027
- Sub-PIU01AI069923-21Caribbean, Central, and South America network for HIV Epidemiology (CCASAnet)National Institute of Allergy and Infectious Diseases · 2006–2027 · via Vanderbilt University Medical Center· 5 renewals
- KP75D30121C10170Tuberculosis Trials Consortium (TBTC) Clinical Research ServicesCenters for Disease Control and Prevention · 2021–2026
- Co-IUM1AI069421-15GHESKIO HIV Clinical Trial Unit (CTU)National Institute of Allergy and Infectious Diseases · 2007–2026 · via GHESKIO Centers· 2 renewals
- Sub-PINU2GGH002383-02Comprehensive HIV/AIDS Service Delivery Programs in Haiti under the President's Emergency Plan for AIDS Relief (PEPFAR)Centers for Disease Control and Prevention · 2021–2026 · via GHESKIO CentersNo publications yet
- Co-IU19AI162568-01Determinants of TB control, relapse and reinfectionNational Institute of Allergy and Infectious Diseases · 2021–2026
- Co-ID43TW011295-03Research Training Program in Adolescent HIV in HaitiFogarty International Center · 2020–2025 · via GHESKIO Centers
Completed grants (21)
- Co-IR21TW011693-01Treatment of early hypertension in persons living with HIV for cardiovascular disease prevention in HaitiFogarty International Center · 2020–2023
- Co-IR01HD091935-04FANMI: Community Cohort Care for HIV-infected Adolescent Girls in HaitiEunice Kennedy Shriver National Institute of Child Health and Human Development · 2017–2022
- Co-IVS 202024-01Development and Implementation of National Primary-Care Hypertension Guidelines in HaitiVital Strategies · 2019–2022
- Sub-PINU2GGH001924-01Reinforcing Capacity at Two Centers of Excellence to Sustain the Delivery of Comprehensive HIV Clinical Services in Haiti Under the President’s Emergency Plan for AIDS Relief (PEPFAR)Centers for Disease Control and Prevention · 2016–2021 · via GHESKIO CentersNo publications yet
- Co-IU19AI111143-06S1Tri-Institutional TB Research Unit: Persistence and LatencyNational Institute of Allergy and Infectious Diseases · 2014–2021· 2 renewals
- Co-IR01AI124349-03Human Genetics of TB Resistance in HIV-Infected PersonsNational Institute of Allergy and Infectious Diseases · 2016–2021 · via McGill University
- KPD43TW010062-04Research Training Program in the Diagnosis, Treatment, and Prevention of AIDS-related MDR-TB in HaitiFogarty International Center · 2015–2021
- Sub-PIR34MH114739-03Immediate Fast-Track Versus Standard Care for Persons Living With HIV in Haiti: A Randomized Pilot StudyNational Institute of Mental Health · 2018–2020 · via The Brigham & Women's Hospital INC
- Sub-PIR01AI131998-03A Trial of Same-Day Testing and Treatment to Improve Outcomes Among Symptomatic Patients Newly Diagnosed With HIVNational Institute of Allergy and Infectious Diseases · 2017–2020 · via The Brigham & Women's Hospital INC
- Sub-PINU2GGH001969-01Strengthening HIV Clinical Services Within a Network of Public and Private Health Institutions in the West, South, and NorthCenters for Disease Control and Prevention · 2016–2019 · via GHESKIO CentersNo publications yet
- Co-ID43TW009606-05 EWOFResearch Training for AIDS Related Cervical Cancer Prevention in HaitiFogarty International Center · 2013–2019
- MPIUM1AI068636-10AIDS Clinical Trials GroupNational Institute of Allergy and Infectious Diseases · 2014–2016 · via The Brigham & Women's Hospital INC
- PIU2GGH000541-05S1GH11-11112: IMPROVEMENT OF INTEGRATED HIV CLINICAL-BASED SERVICESNIH · 2011–2016 · via NIH RePORTERNo publications yet
- MPIU2GGH000545-05S1GH11-1191, Haiti: IMPROVEMENT OF INTEGRATED HIV CLINICAL-BASED SERVICESNIH · 2011–2016 · via NIH RePORTERNo publications yet
- MPIR25TW009337-03S3VUMC 52980: Vanderbilt-Emory-Cornell-Duke Consortium for Global Health Fellows (VECDor)Fogarty International Center · 2014–2016 · via Vanderbilt University· 2 renewals
- KPR01CA142422-01A2Natural History and Pathogenesis of HPV/HIV Co-Infection in HaitiNational Cancer Institute · 2010–2014
- KPU2RTW006896-10Haiti AIDS Research Training: Models to ImplementationFogarty International Center · 2009–2014 · via GHESKIO Centers
- PIU62PS025156-05S1STRENGTHEN & EXPAND ARV TREATMENT IN HAITI TO HIV/AIDS INFECTED POPULATIONSNIH · 2005–2012 · via NIH RePORTERNo publications yet
- PIU01AI058257-05S1Haitian Program for Research and Training in HIV/AIDSNIAID · 2004–2011 · via NIH RePORTER
Honors & distinctions
3 honors
- Fellow · American Academy of Arts and Sciences · 2022
- Joan and Sanford I. Weill Exemplary Achievement Award · Weill Cornell Medicine · 2018
- Member · National Academy of Medicine · 2003
Clinical research
15 studies
Active
4 studies- PINCT06192160A Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary TuberculosisPHASE2 · AIDS Clinical Trial Group · OPEN TO ACCRUAL (as of 2025)Pulmonary Tuberculosis
- PIAn Observational Study of People Receiving Treatment for Multi-drug Resistant Tuberculosis in Haiti_x000D_National Institute of Allergy & Infectious Diseases · OPEN TO ACCRUAL (as of 2024)
- PIIncidence, Pathogenicity and Emergence of SARS-CoV-2 Variants in Pregnant Women and Children in Haiti: A Longitudinal Cohort Study version 1.0 dated 8 Feb 2022GHESKIO Centers · OPEN TO ACCRUAL (as of 2023)
- PIAdolescent and Young Adult Network of IeDEA (AYANI)National Institute of Allergy & Infectious Diseases · OPEN TO ACCRUAL (as of 2022)
Completed & closed trials (11)
- PINCT04311944Early Fast-Track Versus Standard Care for Persons With HIV Initiating Tenofovir Disoproxil Fumarate-Lamivudine-Dolutegravir (TLD) in Haiti: A Pilot Randomized TrialNA · GHESKIO Centers · IRB STUDY CLOSURE (as of 2025)HIV-1-infection
- PINCT01936831The Early Bactericidal Activity of High-Dose or Standard-Dose Isoniazid Among Adult Participants With Isoniazid-Resistant or Drug-Sensitive TuberculosisPHASE2 · National Institute of Allergy & Infectious Diseases · IRB STUDY CLOSURE (as of 2025)Tuberculosis
- PINCT04050449Observational Cohort to Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of Tenofovir-Lamivudine-Dolutegravir (TLD) for First- or Second-Line ART or With Rifampin-Containing TB Treatment: The Hakim StudyAIDS Clinical Trial Group · IRB STUDY CLOSURE (as of 2025)HIV-1-infection
- PINCT03568383Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB)PHASE3 · National Institute of Allergy & Infectious Diseases · CLOSED TO ACCRUAL (as of 2025)Tuberculosis, MDR
- PINCT04272242Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected IndividualsPHASE2 · National Institute of Allergy & Infectious Diseases · IRB STUDY CLOSURE (as of 2025)HIV Infection; LTBI
- PIA prospective cohort study of HIV co-infection and other factors associated with short and long-term outcomes in patients with pulmonary tuberculosis.National Institute of Allergy & Infectious Diseases · CLOSED TO ACCRUAL (as of 2024)
- PINCT05007821A Phase II, Prospective, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety/Tolerability of Two Linezolid Dosing Strategies in Combination With a Short Course Regimen for the Treatment of Drug-Resistant Pulmonary TuberculosisPHASE2 · AIDS Clinical Trial Group · CLOSED TO ACCRUAL (as of 2024)Tuberculosis, Multidrug-Resistant; Tuberculosis; Tuberculosis, Pulmonary
- PINCT04265950Multicenter, Randomized, Open-Label Trial in Children and Adolescents to Establish Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIVPHASE4 · Fred Hutchinson Cancer Center · CLOSED TO ACCRUAL (as of 2024)HIV Infection
- PICCASAnet: Caribbean, Central and South America NetworkNational Institute of Allergy & Infectious Diseases · IRB STUDY CLOSURE (as of 2023)
- PINCT04311502A Phase IIc Trial of Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST StudyPHASE2 · National Institute of Allergy & Infectious Diseases · CLOSED TO ACCRUAL (as of 2023)HIV; Tuberculosis
- PINCT04311957A Randomized Non-Inferiority Trial to Compare the Efficacy of Switching From Protease-Inhibitor Based Second-Line Therapy to Bictegravir-Tenofovir Alafenamide-Emtricitabine in Virologically Suppressed Adults in HaitiPHASE4 · GHESKIO Centers · CLOSED TO ACCRUAL (as of 2023)HIV-1-infection; Antiretroviral Therapy
News mentions
6 mentionsView all WCM news ↗
- Dr. Warren Johnson Honored with Weill AwardJune 4, 2025
The Weill Award recognizes an exceptional faculty member whose transformational work enhances health care worldwide.
- Haiti Study Suggests Early-Onset Heart Failure is Prevalent Form of Heart Disease in Low-Income CountriesApril 29, 2024
Early-onset heart failure is alarmingly common in urban Haiti—over 15-fold higher than previously estimated—according to a study conducted by Weill Cornell Medicine researchers in partnership with the Haitian medical organization GHESKIO.
- $5 Million NIH Center Grant Will Support Next Generation TB ResearchSeptember 7, 2022
Weill Cornell Medicine has been awarded a five-year, $5 million grant from the National Institutes of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health to establish a new multi-institutional center for tuberculosis (TB) research and training the next generation of TB investigators.
Show 1 more mention
- Awards and Honors Across Weill Cornell Medicine - March 31, 2021March 31, 2021
Awards, honors, prizes and achievements for the month of March.
Media highlights
1 clip
- He Warned A Massacre Was Coming. No One Listened.The New York Times · October 20, 2026